↓ Skip to main content

Dove Medical Press

Article Metrics

Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab

Overview of attention for article published in Vascular Health and Risk Management, January 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (85th percentile)
  • Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

twitter
17 tweeters
video
1 video uploader

Readers on

mendeley
127 Mendeley
Title
Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab
Published in
Vascular Health and Risk Management, January 2016
DOI 10.2147/vhrm.s89130
Pubmed ID
Authors

Samuel Asirvatham, Tiffany Hu, Vaibhav Vaidya, Tiffany Y Hu, Vaibhav R Vaidya, Samuel J Asirvatham

Abstract

Novel oral anticoagulants (NOACs) are increasingly used in clinical practice, but lack of commercially available reversal agents is a major barrier for mainstream use of these therapies. Specific antidotes to NOACs are under development. Idarucizumab (aDabi-Fab, BI 655075) is a novel humanized mouse monoclonal antibody that binds dabigatran and reverses its anticoagulant effect. In a recent Phase III study (Reversal Effects of Idarucizumab on Active Dabigatran), a 5 g intravenous infusion of idarucizumab resulted in the normalization of dilute thrombin time in 98% and 93% of the two groups studied, with normalization of ecarin-clotting time in 89% and 88% patients. Two other antidotes, andexanet alfa (PRT064445) and ciraparantag (PER977) are also under development for reversal of NOACs. In this review, we discuss commonly encountered management issues with NOACs such as periprocedural management, laboratory monitoring of anticoagulation, and management of bleeding. We review currently available data regarding specific antidotes to NOACs with respect to pharmacology and clinical trials.

Twitter Demographics

The data shown below were collected from the profiles of 17 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 127 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 2%
Slovenia 1 <1%
Unknown 124 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 21 17%
Researcher 17 13%
Student > Doctoral Student 16 13%
Student > Bachelor 16 13%
Other 15 12%
Other 29 23%
Unknown 13 10%
Readers by discipline Count As %
Medicine and Dentistry 76 60%
Pharmacology, Toxicology and Pharmaceutical Science 11 9%
Agricultural and Biological Sciences 8 6%
Chemistry 5 4%
Nursing and Health Professions 2 2%
Other 6 5%
Unknown 19 15%

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 February 2017.
All research outputs
#1,753,218
of 15,462,509 outputs
Outputs from Vascular Health and Risk Management
#52
of 607 outputs
Outputs of similar age
#38,985
of 267,951 outputs
Outputs of similar age from Vascular Health and Risk Management
#3
of 13 outputs
Altmetric has tracked 15,462,509 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 607 research outputs from this source. They receive a mean Attention Score of 5.0. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 267,951 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.